Poor ovarian response in IVF-programs: a new therapeutic approach

Podzolkova N.M.; Koloda Iu.A.

doi:https://doi.org/

References:

Albuquerque L.E., Saconato H., Maciel M.C. Depot versus daily administration of gonadotrophin releasing hormone agonist protocols for pituitary desensitization in assisted reproduction cycles. Cochrane Database Syst Rev 2005; 1: CD002808.
Alviggi C., Clarizia R., Mollo A., Ranieri A., De Placido G. Outlook: who needs LH in ovarian stimulation? Reprod Biomed Online 2006; 12: 599-607.
Alviggi C., Clarizia R., Pettersson K., Mollo A., Humaidan P., Strina I., Coppola M., Ranieri A., D'Uva M., De Placido G. Suboptimal response to GnRHa long protocol is associated with a common LH polymorphism. Reprod Biomed Online 2009; 18: 9-14.
Alviggi C., Humaidan P., Howles C.M., Tredway D., Hillier S.G. Biological versus chronological ovarian age: implications for assisted reproductive technology. Reprod Biol Endocrinol 2009; 22: 101-113.
Baer G., Loumaye E. Curr Med Res Opin 2003; 19: 83-88.
Balasch J., Fábregues F. LH in the follicular phase: neither too high nor too low. Reprod Biomed Online 2006; 12: 406-415.
Balasch J., Miró F., Burzaco I., Casamitjana R., Civico S., Ballescá J.L., Puerto B., Vanrell J.A. The role of luteinizing hormone in human follicle development and oocyte fertility: evidence from in-vitro fertilization in a woman with long-standing hypogonadotrophic hypogonadism and using recombinant human follicle stimulating hormone. Hum Reprod 1995; 10: 1678-1683.
Barrenetxea G., Agirregoikoa J.A., Lopez de Larruzea A., Ganzabal T., Jimenez M.R., Carbonero K., Mandiola M. LH supplementation in ovarian stimulation in poor responder women. A randomized controlled trial. Hum Reprod 2006; 21: Suppl 1: i55.
Basset et al. Reprod Biomed Online 2009; 19: 3: 300-313.
Buehler K., Naether O.G.J. Large multicentre, observational study of a new 2:1 formulation of follitropin alfa and lutropin alfa in assisted reproductive technology (ART) in routine clinical practice. Fertil Steril 2009; 92: Suppl: S54.
De Castro F., Morón F.J., Montoro L., Galán J.J., Hernández D.P., Padilla E.S., Ramírez-Lorca R., Real L.M., Ruiz A. Human controlled ovarian hyperstimulation outcome is a polygenic trait. Pharmacogenetics 2004; 14: 285-293.
De Placido G., Alviggi C., Mollo A., Strina I., Ranieri A., Alviggi E., Wilding M., Varricchio M.T., Borrelli A.L., Conforti S. Effects of recombinant LH (rLH) supplementation during controlled ovarian hypestimulation (COH) in normogonadotrophic women with an initial inadequate response to recombinant FSH (rFSH) after pituitary downregulation. Clin Endocrinol 2004; 60: 637-643.
De Placido G., Alviggi C., Perino A., Strina I., Lisi F., Fasolino A., De Palo R., Ranieri A., Colacurci N., Mollo A., Italian Collaborative Group on Recombinant Human Luteinizing Hormone. Recombinant human LH supplementation versus recombinant human FSH (rFSH) step-up protocol during controlled ovarian stimulation in normogonadotrophic women with initial inadequate ovarian response to rFSH. A multicentre, prospective, randomized controlled trial. Hum Reprod 2005; 20: 390-396.
Devroey P., Boostanfar R., Koper N.P., Mannaerts B.M., Ijzerman-Boon P.C., Fauser B.C., ENGAGE Investigators. A double-blind, non-inferiority randomized controlled trial comparing corifollitropin alfa and recombinant r-hFSH during the first seven days of ovarian stimulation using a GnRH antagonist protocol. Hum Reprod 2009; 24: 3063-3072.
Driebergen R., Baer G. Curr Med Res Opin. 2003; 19:41-46; Baer G., Loumaye E. Curr Med Res Opin 2003; 19: 83-88.
European Recombinant Human LH Study Group. Recombinant human luteinizing hormone (LH) to support recombinant human follicle-stimulatin hormone (FSH)-induced follicular development in LH- and FSH deficient anovulatory women: a dose-finding study. J Clin Endocrinol Metab 1998; 83: 1507-1554.
Fábregues F., Creus M., Peñarrubia J., Manau D., Vanrell J.A., Balasch J. Effects of recombinant human luteinizing hormone supplementation on ovarian stimulation and the implantation rate in down-regulated women of advanced reproductive age. Fertil Steril 2006; 85: 925-931.
Ferraretti A.P., Gianaroli L., Magli M.C., D'Angelo, Farfalli V., Montanaro N. Exogenous luteinizing hormone in controlled ovarian hyperstimulation for assisted reproduction techniques. Fertil Steril 2004; 82: 1521-1526.
Filicori M., Cognigni G.E., Tabarelli C., Pocognoli P., Taraborrelli S., Spettoli D., Ciampaglia W. Stimulation and growth of antral ovarian follicles by selective LH activity administration in women. J Clin Endocrinol Metab 2002; 87: 1156-1161.
Hillier S.G. Current concepts of the roles of follicle stimulating hormone and luteinizing hormone in folliculogenesis. Hum Reprod 1994; 9: 188-191.
Howles C.M., Kim C.H., Elder K. Treatment strategies in assisted reproduction for women of advanced maternal age. Int Surg 2006; 91: S37-S54.
Hull M., Corrigan E., Piazzi A., Loumaye E. Recombinant human luteinizing hormone: an effective new gonadotropin preparation. Lancet 1994; 344: 334-335.
Humaidan P., Bungum M., Bungum L., Yding Andersen C. Effects of recombinant LH supplementation in women undergoing assisted reproduction with GnRH agonist down-regulation and stimulation with recombinant FSH: an opening study. Reprod Biomed Online 2004; 8: 635-643.
Kailasam C., Keay S.D., Wilson P., Ford W.C., Jenkins J.M. Defining poor ovarian response during IVF cycles, in women aged <40 years, and its relationship with treatment outcome. Hum Reprod 2004; 19: 1544-1547.
Lamminen T., Huhtaniemi I. A common genetic variant of luteinizing hormone; relation to normal and aberrant pituitary-gonadal function. Eur J Pharmacol 2001; 414: 1-7.
Marrs R., Meldrum D., Muasher S., Schoolcraft W., Werlin L., Kelly E. Randomized trial to compare the effect of recombinant human FSH (follitropin alfa) with or without recombinant human LH in women undergoing assisted reproduction treatment. Reprod Biomed Online 2004; 8: 175-182.
Matorras R., Prieto B., Exposito A., Mendoza R., Crisol L., Herranz P., Burgués S. Mid-follicular LH supplementation in women aged 35-39 years undergoing ICSI cycles: a randomized controlled study. Reprod Biomed Online 2009; 19: 879-887.
Mochtar M.H., Van der Veen F., Ziech M., van Wely M. Recombinant luteinizing hormone (rLH) for controlled ovarian hyperstimulation in assisted reproductive cycles. Cochrane Database Syst Rev 2007; 2: CD005070.
Moore A., Penfold L.M., Johnson J.L. et al. Human sperm-egg binding is inhibited by peptides corresponding to core region of an acrosomal serine protease inhibitor. Molecular Reprod Development 1993; 34: 280-291.
Nyboe Andersen A., Humaidan P., Fried G., T.H.E. Nordic rLH study group. Addition of rLH (Luveris) to rFSH during the final days of follicular maturation in IVF/ICSI treated patients. A Nordic randomized multicenter trial. Hum Reprod 2006; 21: Suppl 1: i54.
O'Dea et al. Curr Med Res Opin 2008; 24: 10: 2785-2793.
Picard et al. Curr Med Res Opin 2008; 24: 4: 1199-1208.
RESOLVE: The National Infertility Association nationwide survey finds only 30 percent of patients undergoing infertility treatment are able to administer their medication with one injection per day. Press release May 2006. Available at: http://www.resolve.org. Accessed 9 Oct 2008.
Ruiz Balda J.A., Caballero J.L., Roque A., Ezcurra D. Clinical experience with Pergoveris, a new formulation of rFSH and rLH in a 2:1 ratio, for the treatment of suboptimal patient populations: Spanish preliminary results. Fertil Steril 2009; 92: Suppl: S163.
Ruvolo G., Bosco L., Pane A., Morici G., Cittadini E., Roccheri M.C. Lower apoptosis rate in human cumulus cells after administration of recombinant luteinizing hormone to women undergoing ovarian stimulation for in vitro fertilization procedures. Fertil Steril 2007; 87: 542-546.
Shoham Z., Balen A., Patel A., Jacobs H.S. Results of ovulation induction using human menopausal gonadotropin or purified follicle-stimulating hormone in hypogonadotropic hypogonadism patients. Fertil Steril 1991; 56: 1048-1053.
Shoham Z., Mannaerts B., Insler V., Coelingh-Bennink H. Induction of follicular growth using recombinant human follicle-stimulating hormone in two volunteer women with hypogonadotropic hypogonadism. Fertil Steril 1993; 59: 738-742.
Sun W., Stegmann B.J., Henne W., Catherino W.H., Segars J.H. A new approach to ovarian reserve testing. Fertil Steril 2008; 90: 2196-2202.
Tamura K., Matsushita M., Endo A. et al. Effect of insulin-like growth factor-binding protein 7 on steroidogenesis in granulosa cells derived from equine chorionic gonadotropin-primed immature rat ovaries. Biol Reprod 2007; 77: 485-491.
Tay J.I., Moore J., Walker J.J. Ectopic pregnancy. BMJ 2000; 320: 916-919.
Tsafriri A., Bicsak T.A., Cajander S.B. et al. Suppression of ovulation rate by antibodies to tissue-type plasminogen activator and alpha 2-antiplasmin. Endocrinology 1989; 124: 415-421.
Van der Weier B.H.M. et al. Reprod Biomed Online 2003; 7: 547-557.
Weissman A., Howles C.M. Textbook of assisted reproductive technologies: laboratory and clinical perspectives. 3rd ed. Vol 2. Clinical techniques. London (United Kingdom): Informa UK Ltd 2009; Chapter 44, Treatment strategies in assisted reproduction for the low responder patient; 577-615.
Witsenburg C., Dieben S., Van der Westerlaken L., Verburg H., Naaktgeboren N. Cumulative live birth rates in cohorts of patients treated with in vitro fertilization or intracytoplasmic sperm injection. Fertil Steril 2005; 84: 1: 99-107.
Yarram S.J., Jenkins J., Cole L.A. et al. Epidermal growth factor contamination and concentrations of intact human chorionic gonadotropin in commercial preparations. Fertil Steril 2004; 82: 232-233.
Zorn B., Virant-Klun I., Vidmar G. et al. Seminal elastase-inhibitor complex, a marker of genital tract inflammation, and negative IVF outcome measures: role for a silent inflammation? Int J Androl 2004; 27: 368-374.